MX2020007555A - Anticuerpos potenciadores del factor h y usos de los mismos. - Google Patents
Anticuerpos potenciadores del factor h y usos de los mismos.Info
- Publication number
- MX2020007555A MX2020007555A MX2020007555A MX2020007555A MX2020007555A MX 2020007555 A MX2020007555 A MX 2020007555A MX 2020007555 A MX2020007555 A MX 2020007555A MX 2020007555 A MX2020007555 A MX 2020007555A MX 2020007555 A MX2020007555 A MX 2020007555A
- Authority
- MX
- Mexico
- Prior art keywords
- factor
- antibodies
- fragments
- potentiating antibodies
- complement activation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18151726 | 2018-01-15 | ||
| PCT/NL2019/050018 WO2019139481A1 (en) | 2018-01-15 | 2019-01-15 | Factor h potentiating antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007555A true MX2020007555A (es) | 2021-01-15 |
Family
ID=60972152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007555A MX2020007555A (es) | 2018-01-15 | 2019-01-15 | Anticuerpos potenciadores del factor h y usos de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11377487B2 (https=) |
| EP (1) | EP3740502A1 (https=) |
| JP (2) | JP7471224B2 (https=) |
| KR (2) | KR102896085B1 (https=) |
| CN (1) | CN111868083B (https=) |
| AU (1) | AU2019206207B2 (https=) |
| BR (1) | BR112020014399A2 (https=) |
| CA (1) | CA3088507A1 (https=) |
| IL (1) | IL276008A (https=) |
| MX (1) | MX2020007555A (https=) |
| WO (1) | WO2019139481A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102896085B1 (ko) * | 2018-01-15 | 2025-12-08 | 스티흐팅 산퀸 불드포르지닝 | 인자 h 강화 항체 및 이의 사용 |
| TWI851771B (zh) * | 2019-07-17 | 2024-08-11 | 美商雙子治療子公司 | 因子ｈ增強抗體及其用途 |
| CN114560941B (zh) * | 2020-11-27 | 2024-01-16 | 广东东阳光药业股份有限公司 | Cldn18.2的抗体及其应用 |
| US20250121090A1 (en) * | 2021-07-30 | 2025-04-17 | R.P. Scherer Technologies, Llc | Antibody-Drug Conjugates and Methods of Use Thereof |
| CN116355860A (zh) * | 2021-12-28 | 2023-06-30 | 四川远大蜀阳药业有限责任公司 | 分泌抗h因子抗体的杂交瘤细胞株、抗h因子抗体及其应用 |
| CN116041521B (zh) * | 2022-03-21 | 2023-11-03 | 南京蓬勃生物科技有限公司 | 靶向Siglec-15的单克隆抗体及其应用 |
| NL2032398B1 (en) * | 2022-07-06 | 2024-01-23 | Academisch Ziekenhuis Leiden | Bispecific antibody and uses thereof |
| CN118878671B (zh) * | 2024-07-04 | 2025-09-30 | 南京农业大学 | 抗兽疫链球菌SzM蛋白的猪源化单克隆抗体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013508287A (ja) * | 2009-10-14 | 2013-03-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗体を親和性成熟する方法 |
| CA2780221A1 (en) * | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| CN107074939B (zh) * | 2014-08-20 | 2021-09-07 | 桑昆血液供给基金会 | H因子增强抗体及其用途 |
| KR102485788B1 (ko) * | 2014-08-27 | 2023-01-09 | 메모리얼 슬로안 케터링 캔서 센터 | 항체, 조성물 및 용도 |
| KR102896085B1 (ko) * | 2018-01-15 | 2025-12-08 | 스티흐팅 산퀸 불드포르지닝 | 인자 h 강화 항체 및 이의 사용 |
| TWI851771B (zh) * | 2019-07-17 | 2024-08-11 | 美商雙子治療子公司 | 因子ｈ增強抗體及其用途 |
-
2019
- 2019-01-15 KR KR1020207023681A patent/KR102896085B1/ko active Active
- 2019-01-15 US US16/961,737 patent/US11377487B2/en active Active
- 2019-01-15 CA CA3088507A patent/CA3088507A1/en active Pending
- 2019-01-15 AU AU2019206207A patent/AU2019206207B2/en active Active
- 2019-01-15 CN CN201980019128.3A patent/CN111868083B/zh active Active
- 2019-01-15 JP JP2020538984A patent/JP7471224B2/ja active Active
- 2019-01-15 KR KR1020257040314A patent/KR20250171487A/ko active Pending
- 2019-01-15 BR BR112020014399-5A patent/BR112020014399A2/pt unknown
- 2019-01-15 EP EP19714825.7A patent/EP3740502A1/en active Pending
- 2019-01-15 WO PCT/NL2019/050018 patent/WO2019139481A1/en not_active Ceased
- 2019-01-15 MX MX2020007555A patent/MX2020007555A/es unknown
-
2020
- 2020-07-13 IL IL276008A patent/IL276008A/en unknown
-
2022
- 2022-06-01 US US17/829,688 patent/US20220356235A1/en active Pending
-
2023
- 2023-04-17 JP JP2023067121A patent/JP2023089191A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11377487B2 (en) | 2022-07-05 |
| JP2023089191A (ja) | 2023-06-27 |
| WO2019139481A1 (en) | 2019-07-18 |
| KR20200110688A (ko) | 2020-09-24 |
| US20220356235A1 (en) | 2022-11-10 |
| KR102896085B1 (ko) | 2025-12-08 |
| JP7471224B2 (ja) | 2024-04-19 |
| AU2019206207A1 (en) | 2020-08-13 |
| JP2021510523A (ja) | 2021-04-30 |
| EP3740502A1 (en) | 2020-11-25 |
| IL276008A (en) | 2020-08-31 |
| CN111868083B (zh) | 2025-02-11 |
| CA3088507A1 (en) | 2019-07-18 |
| US20210054059A1 (en) | 2021-02-25 |
| KR20250171487A (ko) | 2025-12-08 |
| CN111868083A (zh) | 2020-10-30 |
| BR112020014399A2 (pt) | 2020-12-29 |
| AU2019206207B2 (en) | 2025-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020007555A (es) | Anticuerpos potenciadores del factor h y usos de los mismos. | |
| PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| MX2020003190A (es) | Degradadores de proteinas y usos de los mismos. | |
| WO2018151821A8 (en) | ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| PH12018501525A1 (en) | Tgfbeta 2 antibodies | |
| PH12018502538A1 (en) | Antibodies to alpha-synuclein and uses thereof | |
| AU2018230657A8 (en) | Anti-C5 antibodies and uses thereof | |
| MX2022007959A (es) | Nuevos anticuerpos anti-fgfr2b. | |
| PH12022551228A1 (en) | Trem2 antibodies and uses thereof | |
| MX2020002435A (es) | Agentes que modulan las funciones de beta-catenina y sus métodos. | |
| MY194603A (en) | Anti-Complement Factor Bb Antibodies And Uses Thereof | |
| MX2019011252A (es) | Anticuerpos anti-c5a y usos de los mismos. | |
| MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
| PH12020550023A1 (en) | Compositions for treating stress-related disorders | |
| PH12018502275A1 (en) | Interferon beta antibodies and uses thereof | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| EP4218817A3 (en) | Methods for treating metabolic diseases by inhibiting myostatin activation | |
| ZA202006216B (en) | Antibodies targeting glycoprotein vi | |
| MX390865B (es) | Composiciones y metodos para el tratamiento de complicaciones y trastornos que se relacionan con el factor de von willebrand | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
| ZA202106807B (en) | Antibodies having specificity for btn2 and uses thereof | |
| MX2020010092A (es) | Variantes de anticuerpo c-terminales. |